首页 | 本学科首页   官方微博 | 高级检索  
     


Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria
Authors:Nils Kroeger MD  Wanling Xie PhD  Jae‐Lyn Lee MD  Georg A. Bjarnason MD  Jennifer J. Knox MD  Mary J. MacKenzie MD  Lori Wood MD  Sandy Srinivas MD  Ulka N. Vaishamayan MD  Sun‐Young Rha MD  Sumanta K. Pal MD  Takeshi Yuasa MD  Frede Donskov MD  Neeraj Agarwal MD  Christian K. Kollmannsberger MD  Min‐Han Tan MD  Scott A. North MD  Brian I. Rini MD  Toni K. Choueiri MD  Daniel Y.C. Heng MD
Affiliation:1. Tom Baker Cancer Center, , Calgary, Alberta, Canada;2. University Medicine Greifswald, Department of Urology, , Germany;3. Dana‐Farber Cancer Institute, , Boston, Massachusetts;4. University of Ulsan College of Medicine, , Asan, South Korea;5. Sunnybrook Odette Cancer Centre, , Toronto, Ontario, Canada;6. Princess Margaret Hospital, University of Toronto, , Toronto, Ontario, Canada;7. London Health Sciences Center, , London, Ontario, Canada;8. Queen Elizabeth II Health Sciences Center, , Halifax, Nova Scotia, Canada;9. Stanford Cancer Institute, Stanford University, School of Medicine, , Stanford, California;10. Karmanos Cancer Institute, Wayne State University, , Detroit, Michigan;11. Yonsei Cancer Centre, Yonsei University College of Medicine, , Seoul, South Korea;12. Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, , Duarte, California;13. Departments of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, , Tokyo, Japan;14. Department of Oncology, Aarhus University Hospital, , Aarhus, Denmark;15. University of Utah Huntsman Cancer Institute, , Salt Lake City, Utah;16. Vancouver Cancer Center, British Columbia Cancer Agency, , Vancouver, British Columbia, Canada;17. Department of Medical Oncology, National Cancer Centre and Institute of Bioengineering and Nanotechnology, , Singapore;18. Cross Cancer Center, University of Alberta, , Edmonton, Alberta, Canada;19. Taussig Cancer Institute, Cleveland Clinic Foundation, , Cleveland, Ohio;20. Harvard Medical School, , Boston, Massachusetts;21. Brigham and Women's Hospital, , Boston, Massachusetts
Abstract:
Keywords:non–  clear cell renal cell carcinoma  targeted therapies  overall survival  prognostication  Heng risk criteria  IMDC risk model
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号